person · Reporting owner
Jones Mitchell Lawrence
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | See Remarks | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,683,757 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 2,620,850 · Balance 2,714,859 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Row 2 · 2026-10-06 · Tax withholding · Disposed 1,031,102 · Balance 1,683,757 F2: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,110,534 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 2,555,266 · Balance 5,110,534 F3: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 590,249 |
Reported balance
After 2026-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-06 · Exercise / conversion · Disposed 65,584 · Balance 590,249 F3: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs.
F3: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F4: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
F5: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 65,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046202 · ownership.xml · derivative · entry 4 Jones Mitchell Lawrence · CIK 0001993292 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,249 Underlying: Common Stock · 65,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F5 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following ten quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 2,555,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046202 · ownership.xml · derivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,110,534 Underlying: Common Stock · 2,555,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F4 · derivative.expiration_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock | 1,031,102 | $1.49 | $1,536,341.98 |
DisclosureSEC source: 0001493152-26-046202 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683,757 F2 · kind: Represents the number of shares of common stock the Issuer has withheld to satisfy the Reporting Person's income tax withholding and remittance obligations as part of the settlement of vested RSUs. Accordingly, no shares of common stock will be sold in the public market to satisfy such income tax withholding and remittance obligations associated with the settlement of these vested RSUs. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 01:35 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 2,620,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-046202 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,714,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| July 07, 2026 Filed Jul 8, 2026 22:52 UTC | PALISADE BIO, INC. PALI · Entity 5803 | SaleCommon Stock | 51,880 | $2.05 | $106,535.58 |
DisclosureSEC source: 0001493152-26-032561 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 F3 · kind: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 22:52 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 131,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-032561 · ownership.xml · derivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,833 Underlying: Common Stock · 131,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F6 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 22:52 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 131,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-032561 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. F2 · balance_after: Includes 1,459 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 01:10 UTC | PALISADE BIO, INC. PALI · Entity 5803 | SaleCommon Stock | 1,989 | $1.75 | $3,480.75 |
DisclosureSEC source: 0001493152-26-006833 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,263 F3 · kind: The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 01:10 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006833 · ownership.xml · derivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F5 · derivative.expiration_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 01:10 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-006833 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. F2 · balance_after: Includes 3,400 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 22:34 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 787,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006257 · ownership.xml · derivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 787,000 Underlying: Common Stock · 787,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:41 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 7,665,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-017477 · ownership.xml · derivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,665,800 Underlying: Common Stock · 7,665,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 13:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantPhantom Units · Derivative | 289,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-012691 · ownership.xml · derivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,000 Underlying: Common Stock · 289,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.exercise_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. F2 · derivative.expiration_date: The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.expiration_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:58 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-006500 · ownership.xml · derivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. F3 · derivative.expiration_date: The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:58 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001493152-25-006500 · ownership.xml · derivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in twelve equal quarterly installments over a three-year period with vesting commencing on May 11, 2025, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 1,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · derivative · entry 6 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: This restricted stock unit was granted on November 21 2024, and all remaining 1,555 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F7 · derivative.exercise_price: This restricted stock unit was granted on November 21 2024, and all remaining 1,555 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F7 · price: This restricted stock unit was granted on November 21 2024, and all remaining 1,555 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 2,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · derivative · entry 5 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,735 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: This restricted stock unit was granted on September 5, 2023, and all remaining 2,735 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F6 · derivative.exercise_price: This restricted stock unit was granted on September 5, 2023, and all remaining 2,735 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F6 · price: This restricted stock unit was granted on September 5, 2023, and all remaining 2,735 restricted stock units subject to the award were accelerated and vested on May 28, 2024 by the Compensation Committee of the Issuer. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 461 | $4.76 | $2,194.36 |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · nonDerivative · entry 4 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,852 F4 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. F4 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 1,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · nonDerivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 810 | $4.76 | $3,855.60 |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,758 F2 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. F2 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 2,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-022038 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 156 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · derivative · entry 6 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,555 Underlying: Common Stock · 156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: This restricted stock unit was granted on November 21, 2023, and 156 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,555 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F7 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023, and 156 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,555 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F7 · price: This restricted stock unit was granted on November 21, 2023, and 156 restricted stock units subject to the award vested on May 6, 2024, and an additional 1,555 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · derivative · entry 5 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,735 Underlying: Common Stock · 304 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: This restricted stock unit was granted on September 5, 2023, and 304 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,735 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · derivative.exercise_price: This restricted stock unit was granted on September 5, 2023, and 304 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,735 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · price: This restricted stock unit was granted on September 5, 2023, and 304 restricted stock units subject to the award vested on May 6, 2024, and an additional 2,735 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F5 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 47 | $8.46 | $397.62 |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · nonDerivative · entry 4 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833 F4 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. F4 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 3. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 156 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · nonDerivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F3 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 90 | $8.46 | $761.40 |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724 F2 · security: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. F2 · shares: Represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the restricted stock units referenced in footnote 1. Read SEC document |
| May 06, 2024 Filed May 8, 2024 22:37 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 304 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-018284 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · CEO, CFO, Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 2,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005482 · ownership.xml · derivative · entry 5 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,667 Underlying: Common Stock · 2,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: This restricted stock unit was granted on November 21, 2023, and 2,333 restricted stock units subject to the award vested on February 6, 2024, and an additional 25,667 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · derivative.exercise_price: This restricted stock unit was granted on November 21, 2023, and 2,333 restricted stock units subject to the award vested on February 6, 2024, and an additional 25,667 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F6 · price: This restricted stock unit was granted on November 21, 2023, and 2,333 restricted stock units subject to the award vested on February 6, 2024, and an additional 25,667 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 4,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-005482 · ownership.xml · derivative · entry 4 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,586 Underlying: Common Stock · 4,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This restricted stock unit was granted on September 5, 2023, and 4,558 restricted stock units subject to the award vested on February 6, 2024, and an additional 45,586 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · derivative.exercise_price: This restricted stock unit was granted on September 5, 2023, and 4,558 restricted stock units subject to the award vested on February 6, 2024, and an additional 45,586 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · price: This restricted stock unit was granted on September 5, 2023, and 4,558 restricted stock units subject to the award vested on February 6, 2024, and an additional 45,586 restricted stock units will vest in equal quarterly installments over the remaining portion of the three-year period from the grant date, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 2,153 | $0.44 | $938.92 |
DisclosureSEC source: 0001493152-24-005482 · ownership.xml · nonDerivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,662 F3 · security: Represents shares sold on behalf of Reporting Person to satisfy tax requirements related to the vesting of the restricted stock units for each of the vested portions of the grant. F3 · price: Represents shares sold on behalf of Reporting Person to satisfy tax requirements related to the vesting of the restricted stock units for each of the vested portions of the grant. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 2,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005482 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F2 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. F2 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on November 21, 2023. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:38 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 4,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-005482 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on September 5, 2023. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 33,160 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042664 · ownership.xml · derivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,160 Underlying: Common Stock · 33,160 shares Expires 2033-11-21 F1 · security: The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F6 · security: The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. F6 · derivative.exercise_date: The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042664 · ownership.xml · derivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires not disclosed F1 · security: The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. F2 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · security: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F3 · derivative.exercise_price: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F2 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. F4 · derivative.expiration_date: N/A. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 22:01 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Tax withholdingCommon Stock, par value $0.01 | 1,630 | $0.54 | $878.41 |
DisclosureSEC source: 0001493152-23-039935 · ownership.xml · nonDerivative · entry 2 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,926 F2 · security: Represents shares sold on behalf of Reporting Person to satisfy tax requirements related to the vesting of the restricted stock units. F2 · price: Represents shares sold on behalf of Reporting Person to satisfy tax requirements related to the vesting of the restricted stock units. Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 22:01 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 4,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-039935 · ownership.xml · derivative · entry 3 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,144 Underlying: Common Stock · 4,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: This restricted stock unit was granted on September 5, 2023, and 4,556 restricted stock units subject to the award vested on November 6, 2023, and an additional 50,144 restricted stock units will vest in equal installments over the eleven (11) quarterly periods thereafter, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. F3 · derivative.expiration_date: This restricted stock unit was granted on September 5, 2023, and 4,556 restricted stock units subject to the award vested on November 6, 2023, and an additional 50,144 restricted stock units will vest in equal installments over the eleven (11) quarterly periods thereafter, subject to Reporting Person continuing to be a service provider to Issuer at the time of vesting. Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 22:01 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock, par value $0.01 | 4,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-039935 · ownership.xml · nonDerivative · entry 1 Jones Mitchell Lawrence · CIK 0001993292 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.